Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03651583
Other study ID # Kiko Protocol 01
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date January 2006
Est. completion date May 2006

Study information

Verified date August 2018
Source Regional Clinical Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot study hopes to show that after 3 months of Kiko training, Kiko naive patients with migraine will have a decrease in the frequency and severity of their migraines.


Description:

3.1 Study Design

Eligible subjects in this pilot study will be taught a series of Kiko exercises. Subjects who meet inclusion and exclusion criteria at the screening visit will be given a diary in which they will document their migraine frequency and severity for one month. Once subject diaries are complete, subjects will meet for a group lesson to learn the background of Kiko and study exercises. A DVD or videotape will be issued for subjects to use during practice at home. Subjects will maintain a diary of their migraine headaches, as well as a diary of their exercise routines. Subjects will meet weekly to reinforce training and encourage training continuation. Diaries will be collected at the end of the first, second, and third months.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date May 2006
Est. primary completion date May 2006
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Males or females, 18 to 70 years of age, with at least a 1-year history of migraine headaches

- With or without aura, (IHS criteria 1.1 and 1.2), who have experienced at least 4 migraines a month, or 2-3 migraines a month that last 2-3 days per attack in each of the 3 months prior to screening.

- The subjects must be naïve to Kiko and Qigong training.

Exclusion Criteria:

1. Subject has any cardiac condition, as determined by the investigator, that would preclude safe participation in a low level exercise program.

2. Uncontrolled hypertension at screening (sitting systolic pressure >160 mmHg, diastolic pressure >95 mmHg.)

3. Subject has had tension-type headaches, >15 days/month in any of the 3 months prior to screening.

4. Subject has more than 8 migraines per month, or more than 16 days of migraine per month.

5. Subject is pregnant or expects to become pregnant during the course of the trial.

6. Subject has substance or alcohol abuse within the the last year which, in the investigator's judgement, will interfere with the study conduct, cooperation or evaluation and interpretation of the study results.

7. Subject has any concurrent medical or psychological condition that, in the investigator's opinion, may affect the interpretation of efficacy or safety data or which otherwise contraindicates participation in the trial.

8. Subject has participated in an investigational drug trial within the previous 4 weeks.

9. Subject uses pain medication in excess of 40 doses of over the counter medication and/or prescription pain medication per month to treat headaches of any type.

10. Subject is unable to differentiate between migraine and non-migraine headaches.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Kiko exercises-combines breathing and movement


Locations

Country Name City State
United States Endwell Family Physicians Endwell New York

Sponsors (1)

Lead Sponsor Collaborator
Regional Clinical Research

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Migraine Frequency and Severity from Baseline Change in Migraine Frequency and Severity from Baseline on LIkert Scale 1-4 3 months
Secondary Change in number of headache free days Change in number of headache free days from baseline based on Diary Data 3 months
Secondary Change in number of migraine free days Change in number of Migraine free days from baseline based on diary data 3 months
Secondary Change in overall quality of life Change in quality of life from baseline based on LIkert scale 1-2 3 month
Secondary Subject satisfaction with Kiko training Satisfaction measurement of training based on LIkert scale 1-5 3 months
See also
  Status Clinical Trial Phase
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Not yet recruiting NCT05943457 - Vitamin K2 Supplementation in Adult Episodic Migraine N/A
Completed NCT01211145 - Zomig - Treatment of Acute Migraine Headache in Adolescents Phase 4
Completed NCT00530517 - A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack Phase 2
Completed NCT00898677 - Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030) Phase 3
Completed NCT03971071 - A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache Phase 4
Withdrawn NCT02706015 - Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks Phase 3
Completed NCT02518464 - Ticagrelor Therapy for RefrACTORy Migraine Study Phase 4
Terminated NCT02375789 - Intranasal Cooling for Symptomatic Relief of Migraine N/A
Terminated NCT00391755 - A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches Phase 4
Completed NCT03401346 - Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults Phase 1
Completed NCT05085483 - Ketone for Migraine Prevention N/A
Completed NCT01604785 - Low-dose Propofol for Pediatric Migraine Phase 2/Phase 3
Terminated NCT00804973 - Study in Participants With Acute Migraines Headaches Phase 2
Completed NCT03341689 - Psilocybin for the Treatment of Migraine Headache Phase 1
Completed NCT01630044 - Neurostimulation Device for Treatment of Migraine Headache N/A
Active, not recruiting NCT00285402 - Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine Phase 2
Completed NCT00203255 - Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache N/A
Recruiting NCT06046508 - Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)
Active, not recruiting NCT04584762 - Automated Variable Pattern Insufflator Device (AVPI) for the Acute Treatment of Migraine N/A